Silver shield: could a simple dressing cut LVAD infections?
NCT ID NCT05163392
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a silver-coated dressing (Silverlon) could reduce infections where the LVAD driveline exits the body. Twenty-five adults with a new LVAD were randomly assigned to receive either the silver dressing or a standard one. Researchers tracked infection rates, comfort, and cost over a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Silverlon (silver-plated biopatch)
- What this could lead to
- If it works, this could reduce the risk of serious infections in people with LVADs, improving their quality of life and reducing hospital visits.
- What could go wrong
- This is a very small pilot study with only 25 participants, so results may not apply to everyone. The dressing might not significantly lower infection rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LVAD (LEFT VENTRICULAR ASSIST DEVICE) DRIVELINE INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSF Parnassus
San Francisco, California, 94143, United States